NWGN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 NWGN pulled ahead of the other in Year 1
Combined, NWGN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NWGN + ABBV for your $10,000?
NewGen Technologies Inc., a fuel production and distribution company, manufactures and distributes renewable biofuels and hydrocarbon blends in the United States. Its products include proprietary and complex technology that improves the performance of gasoline and diesel fuels, as well as alternative fuels, such as ethanol-based E85 and biodiesel-based B20 blends. NewGen Technologies own fuel terminal storage and distribution terminals, as well as a network of wholesale and retail outlets in southeast. The company has joint venture with Advanced Biotechnologies, Inc.; PowerSHIFT Energy Company, Inc.; and Palmbio Venture Pte Lte for manufacturing, processing, storing, marketing, distributing, and selling biodiesel, biodiesel mixtures, and biodiesel byproducts. NewGen Technologies also has a joint venture with Actanol Service, Ltd. to provide energy and biofuel plant solutions; and a strategic agreement with Granite Group Chicago LLC for the rights to develop a gas station/convenience-store prototype. The company was founded in 2005 and is based in Charlotte, North Carolina.
Full NWGN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.